AstraZeneca also confirmed it would would buy Actavis's branded respiratory business in the U.S. and Canada for an initial $600 million plus an additional $100 million. The deal is expected to complete by the end of March.
"With the addition of (respiratory drugs) Tudorza and Daliresp, we will benefit from an immediate boost to revenue in our biggest market, further strengthening our growing respiratory franchise," said Paul Hudson, president of AstraZeneca U.S., in a news release.
The company also declared a second interim dividend of $1.90 per share, bringing the dividend for the full year to $2.80.
The company received a record six product approvals in 2014. These included Duaklir Genuair, a drug used to treat chronic obstructive pulmonary disease, which was approved by the European Commission in November.
The big story for 2014 however was Pfizer's £69 billion ($105 billion) attempted takeover of AstraZeneca. The bid, which failed, would have allowed Pfizer to benefit from lower tax rates and gain a new pipeline of drugs, but was fiercely resisted by AstraZeneca and some U.K. politicians.